Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.33
NAS:THRX's Cash to Debt is ranked higher than
52% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. NAS:THRX: 0.33 )
NAS:THRX' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: 0.33

Equity to Asset -0.43
NAS:THRX's Equity to Asset is ranked higher than
51% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:THRX: -0.43 )
NAS:THRX' s 10-Year Equity to Asset Range
Min: -2.39   Max: 0.67
Current: -0.43

-2.39
0.67
F-Score: 4
Z-Score: -3.37
M-Score: 20.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -911.18
NAS:THRX's Operating margin (%) is ranked higher than
54% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. NAS:THRX: -911.18 )
NAS:THRX' s 10-Year Operating margin (%) Range
Min: -53258.33   Max: -9.58
Current: -911.18

-53258.33
-9.58
Net-margin (%) -1796.37
NAS:THRX's Net-margin (%) is ranked higher than
53% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. NAS:THRX: -1796.37 )
NAS:THRX' s 10-Year Net-margin (%) Range
Min: -50786.54   Max: -13.66
Current: -1796.37

-50786.54
-13.66
ROE (%) -444.65
NAS:THRX's ROE (%) is ranked higher than
54% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. NAS:THRX: -444.65 )
NAS:THRX' s 10-Year ROE (%) Range
Min: -444.65   Max: -54.55
Current: -444.65

-444.65
-54.55
ROA (%) -28.39
NAS:THRX's ROA (%) is ranked higher than
71% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. NAS:THRX: -28.39 )
NAS:THRX' s 10-Year ROA (%) Range
Min: -82.22   Max: -5.91
Current: -28.39

-82.22
-5.91
ROC (Joel Greenblatt) (%) -2098.48
NAS:THRX's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. NAS:THRX: -2098.48 )
NAS:THRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1267.07   Max: -133.15
Current: -2098.48

-1267.07
-133.15
Revenue Growth (3Y)(%) -35.60
NAS:THRX's Revenue Growth (3Y)(%) is ranked higher than
60% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. NAS:THRX: -35.60 )
NAS:THRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 125.7
Current: -35.6

0
125.7
EBITDA Growth (3Y)(%) -43.80
NAS:THRX's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NAS:THRX: -43.80 )
NAS:THRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.2   Max: -2.8
Current: -43.8

-63.2
-2.8
EPS Growth (3Y)(%) -22.40
NAS:THRX's EPS Growth (3Y)(%) is ranked higher than
86% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. NAS:THRX: -22.40 )
NAS:THRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -47.1   Max: 12.9
Current: -22.4

-47.1
12.9
» NAS:THRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

THRX Guru Trades in Q1 2014

Chuck Royce 22,900 sh (New)
Jean-Marie Eveillard 1,595,520 sh (+5.71%)
Seth Klarman 20,705,801 sh (+2.79%)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jeremy Grantham 32,200 sh (-55.7%)
Jim Simons 136,334 sh (-72.35%)
» More
Q2 2014

THRX Guru Trades in Q2 2014

Richard Perry 1,517,208 sh (New)
Jean-Marie Eveillard 1,595,520 sh (unchged)
Jim Simons Sold Out
Jeremy Grantham Sold Out
Seth Klarman 20,395,056 sh (-1.5%)
Chuck Royce 4,300 sh (-81.22%)
» More
Q3 2014

THRX Guru Trades in Q3 2014

Richard Perry 1,831,099 sh (+20.69%)
Chuck Royce Sold Out
Jean-Marie Eveillard 1,593,620 sh (-0.12%)
Seth Klarman 19,815,983 sh (-2.84%)
» More
Q4 2014

THRX Guru Trades in Q4 2014

Richard Perry 4,026,736 sh (+119.91%)
Jean-Marie Eveillard 1,593,620 sh (unchged)
Seth Klarman 19,815,983 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:THRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Perry 2014-12-31 Add 119.91%1.31%$12.9 - $18.64 $ 19.2228%4026736
Seth Klarman 2014-09-30 Reduce -2.84%0.28%$17.53 - $30.4 $ 19.22-16%19815983
Richard Perry 2014-09-30 Add 20.69%0.19%$17.53 - $30.4 $ 19.22-16%1831099
Richard Perry 2014-06-30 New Buy1.2%$21.154 - $30.1 $ 19.22-20%1517208
Seth Klarman 2014-06-30 Reduce -1.5%0.23%$21.154 - $30.1 $ 19.22-20%20395056
Seth Klarman 2014-03-31 Add 2.79%0.42%$24.31 - $32.63 $ 19.22-34%20705801
Seth Klarman 2013-12-31 Add 8.83%1.65%$27.19 - $32.81 $ 19.22-34%20144301
Jean-Marie Eveillard 2013-12-31 Add 23.4%0.03%$27.19 - $32.81 $ 19.22-34%1509404
Seth Klarman 2013-09-30 Add 11.92%2.3%$28.86 - $34.36 $ 19.22-38%18510371
Seth Klarman 2013-06-30 Add 22.02%2.85%$18.15 - $33.74 $ 19.22-28%16538977
Jean-Marie Eveillard 2013-06-30 Add 139.14%0.08%$18.15 - $33.74 $ 19.22-28%1109620
Jean-Marie Eveillard 2012-06-30 Add 24.23%0.01%$14.11 - $19.04 $ 19.2215%509710
Seth Klarman 2012-03-31 Add 2.3%0.22%$13.21 - $16.28 $ 19.2238%14553800
Jean-Marie Eveillard 2012-03-31 Add 25.59%0.01%$13.21 - $16.28 $ 19.2238%410310
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 26.18
THRX's Forward P/E is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. THRX: 26.18 )
N/A
P/S 242.30
THRX's P/S is ranked higher than
66% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. THRX: 242.30 )
THRX' s 10-Year P/S Range
Min: 8.87   Max: 1520
Current: 242.3

8.87
1520
EV-to-EBIT -21.36
THRX's EV-to-EBIT is ranked higher than
74% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. THRX: -21.36 )
THRX' s 10-Year EV-to-EBIT Range
Min: -703.2   Max: -2.2
Current: -21.36

-703.2
-2.2
Current Ratio 18.33
THRX's Current Ratio is ranked higher than
83% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. THRX: 18.33 )
THRX' s 10-Year Current Ratio Range
Min: 2.41   Max: 18.33
Current: 18.33

2.41
18.33
Quick Ratio 18.33
THRX's Quick Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. THRX: 18.33 )
THRX' s 10-Year Quick Ratio Range
Min: 2.41   Max: 18.33
Current: 18.33

2.41
18.33
Days Inventory 9.00
THRX's Days Inventory is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. THRX: 9.00 )
THRX' s 10-Year Days Inventory Range
Min: 0   Max: 0
Current: 9

Days Sales Outstanding 410.62
THRX's Days Sales Outstanding is ranked higher than
67% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. THRX: 410.62 )
THRX' s 10-Year Days Sales Outstanding Range
Min: 2.86   Max: 3530.67
Current: 410.62

2.86
3530.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.60
THRX's Dividend Yield is ranked higher than
84% of the 198 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. THRX: 2.60 )
THRX' s 10-Year Dividend Yield Range
Min: 1.19   Max: 4.44
Current: 2.6

1.19
4.44
Yield on cost (5-Year) 2.50
THRX's Yield on cost (5-Year) is ranked higher than
79% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 1.39 vs. THRX: 2.50 )
THRX' s 10-Year Yield on cost (5-Year) Range
Min: 1.19   Max: 2.22
Current: 2.5

1.19
2.22
Share Buyback Rate -10.90
THRX's Share Buyback Rate is ranked higher than
74% of the 886 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. THRX: -10.90 )
THRX' s 10-Year Share Buyback Rate Range
Min: -2.2   Max: -105.4
Current: -10.9

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -4.60
THRX's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. THRX: -4.60 )
THRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.6   Max: 0
Current: -4.6

-9.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HVE.Germany,
Theravance Inc., was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc. and began operations in May 1997. The Company changed its name to Theravance, Inc. in April 2002.is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Its key programs include: RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, "FF/VI"), ANORO ELLIPTA (umeclidinium bromide/vilanterol, "UMEC/VI") and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with Glaxo Group Limited (GSK), and its Long-Acting Muscarinic Antagonist program. Its drug discovery efforts are based on the principles of multivalency. Multivalency refers to the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets. When compared to monovalency, whereby a molecule attaches to only one binding site, multivalency can significantly increase a compound's potency, duration of action and/or selectivity. Multivalent compounds generally consist of several individual small molecules, at least one of which is biologically active when bound to its target, joined by linking components. The Company has limited in-house active pharmaceutical ingredient (API) production capabilities, and rely primarily on a number of third parties, including contract manufacturing organizations and collaborative partners, to produce active pharmaceutical ingredient and drug product. The development and commercialization of VIBATIV and its product candidates and ongoing research are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for THRX

Headlines

Articles On GuruFocus.com
Richard Perry's Fourth-Quarter Transactions Had High Impact on Portfolio Feb 16 2015 
Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX Dec 05 2014 
Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium Oct 17 2014 
Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer Oct 15 2014 
Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
Seth Klarman's Top 5 Second Quarter Holdings Aug 14 2013 
Top Four from Baupost’s Seth Klarman Jul 18 2013 
What Can We Earn If We Invest in the Top Five Holdings of the Baupost Group? May 29 2013 
Weekly CEO Sells Highlight: Texas Roadhouse Inc., Theravance Inc., AmerisourceBergen Corp. and Nuanc May 06 2013 


More From Other Websites
Arena Pharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Mar 03 2015
Backed by Genentech alum Dave Goeddel, this company looks like the next biotech IPO Mar 02 2015
Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog Mar 02 2015
Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog Mar 02 2015
Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog Mar 02 2015
BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Feb 26 2015
Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Feb 26 2015
Lightning Round: This group goes higher tomorrow Feb 25 2015
Theravance to Present at the Cowen Healthcare Conference Feb 25 2015
Iridian exits position in Wyndham Worldwide Corporation Feb 25 2015
Why Theravance (THRX) Could Be Positioned for a Surge? - Tale of the Tape Feb 25 2015
Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Feb 24 2015
THERAVANCE INC Files SEC form 8-K, Other Events Feb 23 2015
Theravance, Inc. Announces Cash Dividend of $0.25 per Share Payable to Stockholders of Record as of... Feb 23 2015
Iridian boosts its holdings in W.R. Grace and Company by 25% Feb 20 2015
Iridian increases its stake in Theravance Feb 19 2015
Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog Feb 19 2015
Theravance Reports In Line Loss in Q4, Revenues Increase - Analyst Blog Feb 19 2015
Theravance reports 4Q loss Feb 19 2015
Theravance reports 4Q loss Feb 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK